文献速递肿瘤 PET/CT

68Ga-FAPI PET/CT用于转移性多形性小叶乳腺癌分期与疗效评估

Beyond FDG: Serial 68 Ga-FAPI PET/CT for Staging and Treatment Response Assessment in Metastatic Pleomorphic Lobular Breast Cancer.
PubMed 文献 · Clin Nucl Med · 2026-05-15

本文报道一例复发性转移性多形性小叶乳腺癌,基线68Ga-FAPI PET/CT显示的广泛区域及远处病变程度超过18F-FDG PET/CT。启动奥拉帕利治疗后系列随访FAPI PET/CT显示显著应答、病变接近完全消退,提示FAPI PET/CT在小叶乳腺癌疗效评估中的潜在价值。

要点

  • 68Ga-FAPI PET/CT在乳腺癌尤其是浸润性小叶癌中敏感性高于18F-FDG PET/CT。
  • 本例基线FAPI PET/CT显示的病变范围被18F-FDG PET/CT低估。
  • 奥拉帕利治疗后系列FAPI PET/CT示显著应答、病变接近完全消退。

核心结论

  • FAPI PET/CT在小叶乳腺癌疗效评估中可能具有应用价值。

研究设计与样本

  • 本文为单例病例报告,报道一例复发性转移性多形性小叶乳腺癌患者。

主要发现

  • 基线68Ga-FAPI PET/CT显示广泛区域及远处病变,其范围被18F-FDG PET/CT低估。
  • 启动奥拉帕利后系列随访FAPI PET/CT显示显著应答,病变接近完全消退。

临床怎么用

  • 对浸润性小叶乳腺癌可考虑FAPI PET/CT以更全面评估病变范围。
  • FAPI PET/CT可用于奥拉帕利治疗后的系列疗效随访评估。

局限性

  • 仅为单例病例报告,FAPI PET/CT用于疗效评估的作用仍有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68 Ga-FAPI PET/CT has demonstrated higher sensitivity than 18 F-FDG PET/CT in breast cancer, particularly in invasive lobular carcinoma. However, its role in treatment response assessment remains limited. We report a case of recurrent metastatic pleomorphic lobular breast cancer in which baseline 68 Ga-FAPI PET/CT revealed extensive regional and distant disease underestimated by 18 F-FDG PET/CT. Serial follow-up FAPI PET/CT after initiation of olaparib demonstrated marked response with near complete resolution of disease, highlighting the potential utility of FAPI PET/CT for response assessment in lobular breast cancer.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Al Riyami K, Jain A, Al Busaidi A, et al. Beyond FDG: Serial 68 Ga-FAPI PET/CT for Staging and Treatment Response Assessment in Metastatic Pleomorphic Lobular Breast Cancer. Clin Nucl Med. 2026. PMID: 42149908. doi:10.1097/RLU.0000000000006540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。